Securities and Exchange Commission
Washington, DC 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) January 21, 2004
----------------
ASTRALIS LTD.
(Exact Name of Registrant as Specified in its Charter)
Delaware 000-30997 84-1508866
--------------------------------------------------------------------------------
(State or Other (Commission File Number) (IRS Employer
Jurisdiction of Incorporation) Identification No.)
75 Passaic Avenue, Fairfield, New Jersey 07004
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (973) 227-7168
--------------
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits
Exhibit No. Description
99.1 Press Release dated January 21, 2004
ITEM 9. REGULATION FD DISCLOSURE.
On January 21, 2004, the registrant issued a press release regarding
(i) the closing of a private placement and (ii) the conversion by SkyePharma PLC
of shares of Series A Preferred Stock of the registrant into shares of common
stock. A copy of the press release is attached as Exhibit 99.1.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ASTRALIS LTD.
Date: January 21, 2004 By: /s/ Mike Ajnsztajn
---------------------------
Mike Ajnsztajn
Chief Executive Officer